Gefitinib-induced lung injury successfully treated with high-dose corticosteroids

Respirology

Volumn 11, Issue 1, 2006, Pages 113-116

  Seto, Takashi ^a   Seki, Nobuhiko ^a   Uematsu, Kazutsugu ^a   Tanigaki, Toshimori ^a   Shioya, Sumie ^a   Koboyashi, Toshiki ^a   Umemura, Shinobu ^a   Eguchi, Kenji ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

Acute interstitial pneumonia; Early detection; Gefitinib; Non small cell lung cancer

Indexed keywords

CORTICOSTEROID; GEFITINIB; METHYLPREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; HUMAN; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS CELL; LUNG INJURY; LUNG LOBE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; SYMPTOM; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TREATMENT OUTCOME;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PHOTOMICROGRAPHY; QUINAZOLINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645108567     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.00794.x     Document Type: Article

References (16)

1. Arteaga CL Johnson DH Tyrosine kinase inhibitors-ZD1839 (Iressa) CurrOpinOncol 2001 13 491 8
2. Ciardiello F Tortora G A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor ClinCancer Res 2001 7 2958 70
3. Fukuoka M Yano S Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer JClinOncol 2003 21 2227 9
4. Kris MG Natale RB Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 2003 290 2149 58
5. Baselga J Rischin D Ranson M et al. Phase I safety, pharmacokinetic, and phamacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types JClinOncol 2002 20 4292 302
6. Ranson M Hammond LA Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial JClinOncol 2002 20 2240 50
7. Herbst RS Maddox AM Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial JClinOncol 2002 20 3815 25
8. Inoue A Saijo Y Maemonda M et al. Severe acute interstitial pneumonia and gefitinib Lancet 2003 361 137 9
9. Madtes DK Busby HK Strandjord TP Clark JG Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats AmJRespirCell MolBiol 1994 11 540 51
10. Madtes DK Rubenfeld G Klima LD et al. Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome AmJRespirCritCare Med 1998 158 424 30
11. Hardie WD Prows DR Leikauf GD Korfhagen TR Attenuation of acute lung injury in transgenic mice expressing human transforming growth factor-alpha AmJPhysiol 1999 277 L1045 50
12. Hardie WD Prows DR Piljan-Gentle A et al. Dose-related protection from nickel-induced lung injury in transgenic mice expressing human transforming growth factor-alpha AmJRespirCell MolBiol 2002 26 430 7
13. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias AmJRespirCritCare Med 2002 165 277 304
14. Giaccone G Herbst RS Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 JClinOncol 2004 22 777 84
15. Herbst RS Giaccone G Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 JClinOncol 2004 22 785 94
16. Takeda K Yamamoto N An epidemiological survey for interstitial lung disease induced by gefitinib in patients with advanced non-small cell lung cancer Lung Cancer 2003 41 Suppl. 2 250.